Fri. 24 May 2024, 10:01am ET
Benzinga
News, FDA
- Rapid reduction in disease activity seen at 12 weeks was sustained at one year
- 55% of patients showed zero C3c staining intensity, indicating that C3c deposits were cleared
- Highlighted as late-breaking oral presentation at the European Renal Association (ERA) Congress